Search clinical trials for: Nimotuzumab、Tislelizumab

Total 642 results

Peking Union Medical College Hospital

Not yet recruiting

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Cervical Cancer
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Peking University
Biotech Pharmaceutical Co., Ltd.

Unknown

Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

SCCHN
Cancer Institute and Hospital, Chinese Academy...

Unknown

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

Gastric Cancer | Concurrent Chemoradiotherapy

China
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
Peking University

Unknown

Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Cancer

China
Oncoscience AG
Heinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang Goethe... and other collaborators

Completed

Nimotuzumab in Adults With Glioblastoma Multiforma

Adults With Glioblastoma Multiforma

Germany
Oncoscience AG
Heinrich-Heine University, Duesseldorf; University of Wuerzburg; Children's Medical... and other collaborators

Completed

Nimotuzumab in Children With Intrinsic Pontine Glioma

Diffuse Instrinsic Ponitine Glioma

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Chemotherapy | Immunotherapy | Chemoradiotherapy | Nimotuzumab

China
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer (GCR-05)

Cervical Cancer

China
University of Saskatchewan
Western Economic Diversification Canada

Recruiting

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

Lung Cancer

Canada
YM BioSciences
CIMYM BioSciences

Terminated

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Cuba, Pakistan
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
National Institute of Cancerología
National Heart Institute, Mexico; Pisa S.A de C.V

Completed

Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

Palliative Treatment | Cervical Cancer Recurrent or Persistent | Monoclonal Antibody in Cervical Cancer Treatment

Mexico
Peking University
Biotech Pharmaceutical Co., Ltd.

Unknown

Study of Nimotuzumab to Treat Colorectal Cancer

Advanced Colorectal Cancer

China
People's Hospital of Guangxi
Wu Jieping Medical Foundation

Unknown

Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer

Locally Advanced Cervical Cancer

China
Peking University

Unknown

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Esophageal Cancer | Chemotherapy | Immunotherapy | Chemoradiotherapy | Nimotuzumab

China
Tianjin Medical University Cancer Institute and...

Recruiting

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Pancreatic Cancer

China
Sun Yat-sen University

Active, not recruiting

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Withdrawn

Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Biotech Pharmaceutical Co., Ltd.

Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (Redbull-1)

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
YM BioSciences
CIMYM BioSciences

Terminated

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Non-small-cell Lung Cancer

Canada, United States, Singapore
Lei Li

Recruiting

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Recurrent Cervical Carcinoma | Radiotherapy | Objective Response Rate | Overall Survival | Progression-free Survival | Epidermal Growth Factor Receptor | Nimotuzumab

China
Peking Union Medical College Hospital

Active, not recruiting

Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Stomach Neoplasms

China
YM BioSciences
CIMYM BioSciences

Completed

Phase I Study of Nimotuzumab in Solid Tumours

Advanced and/or Metastatic Solid Tumours

Canada
El Kendi Pharmaceuticals Manufacturing Company

Completed

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom (CIMAHOPE)

Cervical Cancer

Algeria
Gilead Sciences

Terminated

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (RAINIER)

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Israel, Australia, Italy, Canada, United Kingdom, Switzerland, Germany, Poland, Czechia, Belgium, France
Sun Yat-sen University

Recruiting

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential Chemoradiation

China
Sun Yat-sen University
Zhejiang Cancer Hospital; Guangxi Medical University; Wuhan University; Fujian... and other collaborators

Completed

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma

China
Anhui Provincial Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma

Toxicity, Drug

China
Fudan University

Completed

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Cervical Cancer
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Guiyang Medical University

Unknown

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Nasopharyngeal Carcinoma

China
Fudan University

Active, not recruiting

Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Shanghai Gopherwood Biotech Co., Ltd.

Recruiting

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Malignant Solid Tumors

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Biotech Pharmaceutical Co., Ltd.

Recruiting

Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Diffuse Intrinsic Pontine Glioma

China
Air Force Military Medical University, China

Unknown

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Cervical Cancer

China
Biotech Pharmaceutical Co., Ltd.
Fudan University; NanJing PLA 81 Hospital

Completed

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Cancer

China

Search clinical trials for: Nimotuzumab、Tislelizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations